Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration

Documenti analoghi

• Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P‐Glycoprotein Substrate
  di: Panli Cardona, et al.
  Pubblicazione: (2025)
• Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage
  di: Panli Cardona, et al.
  Pubblicazione: (2024)
• Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor
  di: Panli Cardona, et al.
  Pubblicazione: (2024)
• Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
  di: Panli Cardona, et al.
  Pubblicazione: (2024)
• Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects
  di: Varsha Iyer, et al.
  Pubblicazione: (2024)